Navigation Links
Team hopes to cut years off development time of new antibiotics
Date:2/11/2011

HOUSTON, Feb. 11, 2011 Eliminating tens of thousands of manual lab experiments, two University of Houston (UH) professors are working toward a method to cut the development time of new antibiotics. While current practices typically last for more than a decade, a computerized modeling system being developed at UH will speed up this process.

Vincent Tam, associate professor of clinical sciences, and Michael Nikolaou, professor of chemical and biomolecular engineering, are focusing on dosing regimens to reveal which ones are most likely to be effective in combating infection and which are not worth pursuing. It is hoped that pharmaceutical companies can then focus their tests on the most promising regimens.

Their findings recently were the subject of a cover story titled "A Novel Approach to Pharmacodynamic Assessment of Antimicrobial Agents: New Insights to Dosing Regimen Design," appearing in the Public Library of Science's PLoS Computational Biology. The journal aims to further the understanding of living systems from molecules to humans through the application of computational methods. This article chronicles the results of a three-year endeavor that was initially funded by a $400,000 grant from the National Science Foundation.

"With microbial resistance to drugs increasing, there is a need to develop new antimicrobial agents rapidly," Tam said. "Our work proposes a new computational method that will provide quantitative insight to the interaction between certain antibiotics and pathogens. Through pharmacodynamic modeling, which studies the effects of drugs on organisms, our aim is to both help develop new antibiotics and optimize existing medications to curb the prevalence of drug-resistant bacteria."

The traditional approach to drug development involves a great deal of trial-and-error testing, such as empirically selecting a handful of dosing regimens for clinical investigations among hundreds of possibiliti
'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Test shows dinosaurs survived mass extinction by 700,000 years
2. The world can be powered by alternative energy, using todays technology, in 20-40 years
3. UF study of lice DNA shows humans first wore clothes 170,000 years ago
4. Without intervention, Mariana crow to become extinct in 75 years
5. 550 million years ago rise in oxygen drove evolution of animal life
6. Decline of West Coast fog brought higher coastal temperatures last 60 years
7. New book on 100 years of Illinois birds
8. Researcher explores the evolution of largest mammals over the past 100 million years
9. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
10. German-Russian Otto Schmidt Laboratory in St. Petersburg funded for another 3 years
11. New statistical model moves human evolution back 3 million years
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Team hopes to cut years off development time of new antibiotics
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Epitomics, Inc. announced today that it has signed a ... HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody ... identification and validation. "Epitomics has had ... is a major expansion of our collaboration and confirms ...
... German . Medicines from plants ... that has nothing in common with what the researchers ... Ecology IME in Aachen, Germany, are doing. They use ... many other medications, cannot be chemically produced. Biologically ...
... persist in the often violently competitive realm of bacteria, ... University Bloomington biologists have learned that in one bacterium, ... cheaters and arrest their bids for dominance. ... suppress social cheaters," said Gregory Velicer, who with Ph.D. ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Groton , Connecticut MORRISVILLE, N.C., May ... of APIs, intermediates and Drug Products to the pharmaceutical industry, ... announce the recent award by Pfizer Inc. as the 2008 ... Groton, Connecticut R&D center on May 1, 2009. The award ...
... Blinatumomab in NHL and ALL Highlighted at the ... Combination Data in Breast Cancer to Be Presented ... MeetingBETHESDA, Md., May 20 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ...
... WOODMERE, N.Y., May 19 In an eleventh-hour attempt ... QGLY ) has issued a press release claiming that ... a key staff member of a subsidiary of Quigley, and ... who have offered their own slate of Quigley,s Board of ...
Cached Biology Technology:Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Proline-serine-threonine phosphatase-interacting protein 2...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: